Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Intas' MD On Acquiring Best-Performing Assets And Brexit

Executive Summary

India's largest privately held pharmaceutical company, Intas, says that it understands Europe well and that the best-performing assets acquired from Teva there are a "perfect fit" for its business. Intas vice chair and managing director Binish Chudgar spoke to Scrip on the buyout and why Brexit isn't a major concern - at least for now.

Advertisement

Related Content

Aurobindo Aims For Europe Growth With Apotex Acquisitions
Intas Builds Europe Scale With £603m Teva Deal
Brexit – Indian Pharma’s Diversified Play A Buffer?
Allergan's UK Generics Business Up For Sale Under EC Merger Condition
Temasek ups India play with $151m Glenmark deal
Intas' biosimilar Enbrel debuts at hefty discount in India

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097431

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel